Associations of serum cytokines and chemokines with the risk of incident cancer in a prospective rheumatoid arthritis cohort.

Autor: England BR; VA Nebraska-Western Iowa Healthcare System, Omaha, NE, USA; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: Bryant.england@unmc.edu., Campany M; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Sayles H; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Roul P; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Yang Y; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Ganti AK; VA Nebraska-Western Iowa Healthcare System, Omaha, NE, USA; Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Sokolove J; Division of Immunology and Rheumatology, Stanford University, Stanford, CA, and the Department of Veterans Affairs, Palo Alto, CA, USA; GlaxoSmithKline, Collegeville, PA, USA(1)., Robinson WH; Division of Immunology and Rheumatology, Stanford University, Stanford, CA, and the Department of Veterans Affairs, Palo Alto, CA, USA., Reimold AM; Dallas VA and University of Texas Southwestern Medical Center, Dallas, TX, USA., Kerr GS; Washington D.C. VA, Howard University, and Georgetown University, Washington D.C., USA., Cannon GW; Salt Lake City VA & University of Utah, Salt Lake City, UT, USA., Sauer BC; Salt Lake City VA & University of Utah, Salt Lake City, UT, USA., Baker JF; Corporal Michael J. Crescenz VA Medical Center & University of Pennsylvania, Philadelphia, PA, USA., Thiele GM; VA Nebraska-Western Iowa Healthcare System, Omaha, NE, USA; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Mikuls TR; VA Nebraska-Western Iowa Healthcare System, Omaha, NE, USA; Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2021 Aug; Vol. 97, pp. 107719. Date of Electronic Publication: 2021 Apr 29.
DOI: 10.1016/j.intimp.2021.107719
Abstrakt: Objectives: We aimed to assess whether serum cytokine/chemokine concentrations predict incident cancer in RA patients.
Methods: Data from cancer-free enrollees in the Veterans Affairs Rheumatoid Arthritis (VARA) Registry were linked to a national VA oncology database and the National Death Index (NDI) to identify incident cancers. Seventeen serum cytokines/chemokines were measured from enrollment serum and an overall weighted cytokine/chemokine score (CK score) was calculated. Associations of cytokines/chemokines with all-site, lung, and lymphoproliferative cancers were assessed in Cox regression models accounting for relevant covariates including age, sex, RA disease activity, and smoking.
Results: In 1216 patients, 146 incident cancers (42 lung and 23 lymphoproliferative cancers) occurred over 10,072 patient-years of follow-up with a median time of 4.6 years from enrollment (cytokine/chemokine measurement) to cancer incidence. In fully adjusted models, CK score was associated with a higher risk of all-site (aHR 1.32, 95% CI 1.01-1.71, p < 0.001), lung (aHR 1.81, 1.40-2.34, p = 0.001), and lung/lymphoproliferative (aHR 1.54 [1.35-1.75], p < 0.001) cancer. The highest quartile of CK score was associated with a higher risk of all-site (aHR 1.91, 0.96-3.81, p = 0.07; p-trend = 0.005), lung (aHR 8.18, 1.63-41.23, p = 0.01; p-trend < 0.001), and lung/lymphoproliferative (aHR 4.56 [1.84-11.31], p = 0.001; p-trend < 0.001) cancer. Thirteen of 17 individual analytes were associated with incident cancer risk.
Conclusion: Elevated cytokine/chemokine concentrations are predictive of future cancer in RA patients, particularly lung and lymphoproliferative cancers. These results suggest that the measurement of circulating cytokines/chemokines could be informative in cancer risk stratification and could provide insight into future cancer prevention strategies in RA, and possibly individuals without RA.
(Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: